These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 36318979)

  • 1. Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study.
    Pradhan R; Lu S; Yin H; Yu OHY; Ernst P; Suissa S; Azoulay L
    BMJ; 2022 Nov; 379():e071380. PubMed ID: 36318979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.
    Fu EL; Wexler DJ; Cromer SJ; Bykov K; Paik JM; Patorno E
    BMJ; 2024 Jun; 385():e078483. PubMed ID: 38925801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
    Simms-Williams N; Treves N; Yin H; Lu S; Yu O; Pradhan R; Renoux C; Suissa S; Azoulay L
    BMJ; 2024 Apr; 385():e078242. PubMed ID: 38663919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
    Fu EL; Mastrorilli J; Bykov K; Wexler DJ; Cervone A; Lin KJ; Patorno E; Paik JM
    Kidney Int; 2024 Mar; 105(3):618-628. PubMed ID: 38101515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes.
    Foer D; Strasser ZH; Cui J; Cahill KN; Boyce JA; Murphy SN; Karlson EW
    Am J Respir Crit Care Med; 2023 Nov; 208(10):1088-1100. PubMed ID: 37647574
    [No Abstract]   [Full Text] [Related]  

  • 6. Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes.
    Pradhan R; Yin H; Yu OHY; Azoulay L
    Diabetes Care; 2022 Oct; 45(10):2289-2298. PubMed ID: 35866685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.
    Faillie JL; Yin H; Yu OHY; Herrero A; Altwegg R; Renoux C; Azoulay L
    Clin Pharmacol Ther; 2022 Jan; 111(1):272-282. PubMed ID: 34587280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
    Abrahami D; Douros A; Yin H; Yu OH; Faillie JL; Montastruc F; Platt RW; Bouganim N; Azoulay L
    BMJ; 2018 Dec; 363():k4880. PubMed ID: 30518618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.
    Pradhan R; Yin H; Yu O; Azoulay L
    Diabetes Care; 2022 Apr; 45(4):819-829. PubMed ID: 35104330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.
    Foer D; Beeler PE; Cui J; Karlson EW; Bates DW; Cahill KN
    Am J Respir Crit Care Med; 2021 Apr; 203(7):831-840. PubMed ID: 33052715
    [No Abstract]   [Full Text] [Related]  

  • 11. Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: A Multisite Population-Based Cohort Study.
    Pradhan R; Patorno E; Tesfaye H; Schneeweiss S; Yin H; Franklin J; Pawar A; Santella C; Yu OHY; Renoux C; Azoulay L
    Am J Epidemiol; 2022 Jul; 191(8):1352-1367. PubMed ID: 35136902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Novel Antihyperglycemic Drugs Versus Metformin With a Decrease in Asthma Exacerbations.
    Kimura Y; Jo T; Inoue N; Suzukawa M; Hashimoto Y; Kumazawa R; Ishimaru M; Matsui H; Yokoyama A; Tanaka G; Sasabuchi Y; Yasunaga H
    J Allergy Clin Immunol Pract; 2024 Aug; 12(8):2035-2044. PubMed ID: 38734374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records.
    Xie Y; Bowe B; Xian H; Loux T; McGill JB; Al-Aly Z
    Lancet Diabetes Endocrinol; 2023 Sep; 11(9):644-656. PubMed ID: 37499675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.
    O'Brien MJ; Karam SL; Wallia A; Kang RH; Cooper AJ; Lancki N; Moran MR; Liss DT; Prospect TA; Ackermann RT
    JAMA Netw Open; 2018 Dec; 1(8):e186125. PubMed ID: 30646315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients With Type 2 Diabetes.
    Lu S; Yin H; Yu OHY; Azoulay L
    Epidemiology; 2022 Jul; 33(4):563-571. PubMed ID: 35394977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study.
    Pradhan R; Yu OHY; Platt RW; Azoulay L
    Diabet Med; 2024 Apr; 41(4):e15248. PubMed ID: 37876318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy.
    Barkmeier AJ; Herrin J; Swarna KS; Deng Y; Polley EC; Umpierrez GE; Galindo RJ; Ross JS; Mickelson MM; McCoy RG
    Ophthalmol Retina; 2024 Oct; 8(10):943-952. PubMed ID: 38735641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Yan Y; Al-Aly Z
    Diabetes Care; 2020 Nov; 43(11):2859-2869. PubMed ID: 32938746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
    Chang HY; Singh S; Mansour O; Baksh S; Alexander GC
    JAMA Intern Med; 2018 Sep; 178(9):1190-1198. PubMed ID: 30105373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.